As Eli Lilly gets off to the races with the launch of its flagship oral GLP-1 Foundayo, the Indianapolis drugmaker—and at ...
As Merck considers its life after Keytruda, much will depend on the performance of a pair of respiratory products it gained ...
The European Medicines Agency (EMA) has launched an advisory group designed to help boost “vaccine confidence” amid growing ...
Novartis will construct an active pharmaceutical ingredient (API) facility in Morrisville, North Carolina, the company said ...
The FDA has reprimanded Bayer for the “attention-grabbing visuals” and “frequent scene changes” in ads for the company’s ...
Patient groups’ perceptions of drugmakers with large U.S. footprints have shifted in the past year as the businesses have ...
As AstraZeneca braces for the impact of the U.S. “most favored nation” drug pricing policy, CEO Pascal Soriot suggests that a ...
Three years after AbbVie stood at the edge of a major patent cliff with the loss of exclusivity for immunology ...
Teva’s overall performance topped Wall Street estimates for Q1, according to Bloomberg News, which also pointed out that the ...
In GSK’s first quarter with Luke Miels as CEO, the company’s flagship shingles vaccine Shingrix set a new quarterly sales ...
Nearly three years after the FDA approved Pfizer's bispecific antibody Elrexfio as a late-line treatment for patients with ...
As Ekterly nears the one-year anniversary of its FDA approval, Italy’s Chiesi Group is making moves to acquire the rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results